Reversion in thymidine kinase deficient variants of mouse lymphoma P388.
The ability of 5 independently isolated thymidine kinase-deficient clones of mouse lymphoma P388 to revert has been examined. We were unable to detect spontaneous revertants in any of the 5 clones. Treatment with the hypomethylating agent 5-azacytidine induced reversion in 4 of the clones, but the frequency of revertants was very low (less than 10(-6). The response was not dose-dependent. The mutagen EMS was capable of inducing reversion in 3 of the clones with a variable level of response. The activity of thymidine kinase in 16 revertants was determined. In half of these the level of enzyme activity was considerably greater than the original P388 cell line. The high frequency loss of thymidine kinase that occurs in these cells may represent a stable inactivation of gene activity rather than an alteration in the DNA base sequence.
Ruddy
S M
SM
Department of Biology, The Queen's University of Belfast, Northern Ireland.
Hickey
I
I
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology*; D007941:Leukemia P388 / Q000201:enzymology* / Q000235:genetics; D007942:Leukemia, Experimental / Q000201:enzymology*; D051379:Mice; D009154:Mutation; D013937:Thymidine Kinase / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
D013937:Thymidine Kinase; D001374:Azacitidine